GET DAILY SIGNALSCellebrite (CLBT) Analyst Targets Point to +26% Upside Potential
Key Takeaways
- The central stock price target of $14.50 is the rounded arithmetic mean of six recent, individually verified analyst price targets, which I calculated at roughly $14.40.
- That target compares with a latest verified price of about $11.53 as of the November 13, 2026 close, implying roughly 26% upside.
- The six recent targets range from $12.50 (Needham) to $15.00 (JPMorgan, D.A. Davidson, Lake Street, and TD Cowen), reflecting a much narrower range after a wave of August 2026 cuts.
- Sentiment is broadly bullish but not unanimous, with most covering firms rating the shares Buy or Overweight while one research provider carries a sell rating.
- The strongest support comes from resilient demand for digital forensics and an attractive setup into 2027 cited by JPMorgan; the biggest risk is the recent fourth-quarter guidance shortfall and weak share-price momentum.
- The stock trades near the lower end of its 52-week range after falling about 14% following its November 12 earnings report.
Breaking Down the Analyst Targets
Cellebrite DI Ltd. (CLBT) is a digital intelligence company whose software and hardware help law enforcement agencies, governments, and enterprises collect, review, and analyze digital evidence. I reviewed six recent, individually attributable price targets rather than relying on any single website's headline consensus. The most current figures are JPMorgan at $15 (November 13, 2026, Overweight), D.A. Davidson at $15 (September 15, 2026, Buy), Lake Street at $15 (August 14, 2026, Buy), TD Cowen at $15 (August 13, 2026, Buy), Deutsche Bank at $14 (August 14, 2026, Buy), and Needham at $12.50 (August 14, 2026, Buy). The arithmetic mean of these six is about $14.40, which I round to a clean $14.50.
The range has narrowed sharply after a cluster of cuts in mid-August, when Lake Street ($21 to $15), TD Cowen ($23 to $15), Deutsche Bank ($20 to $14), and Needham ($15 to $12.50) all reduced targets. Ratings nonetheless remain overwhelmingly positive; JPMorgan explicitly framed the shares as "an attractive setup" into 2027. The main dissent comes from quantitative research provider Weiss Ratings, which has carried a sell rating, which is why the consensus view is best described as bullish but not unanimous. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
As of the November 13, 2026 close, CLBT traded near $11.53, toward the lower end of its 52-week range of $9.58 to $19.98. Reaching $14.50 requires a gain of roughly 26%, a substantial move rather than a modest one, particularly after the stock fell about 14% on November 12 when fourth-quarter revenue guidance disappointed.
The shares have declined roughly 37% over the past year, so the path back toward the mid-teens would likely require not only solid execution but also a restoration of investor confidence in near-term growth. With trailing revenue near $514 million, a gross margin above 80%, and a forward P/E well below its trailing multiple, the valuation has already de-rated considerably, which could make the target achievable if guidance stabilizes.
Factors That Could Support a Move Toward the Target
Cellebrite operates in a durable niche: demand for digital investigation tools is driven by regulation, criminal caseloads, and enterprise data-management needs rather than discretionary spending. Its high gross margin and strong cash position support the business model. JPMorgan's stated view of an "attractive setup" into 2027 suggests analysts see growth re-accelerating after the current reset. Full-year 2026 revenue guidance of roughly $553 million to $558 million was broadly in line with consensus, indicating the annual outlook held up even as the quarterly guide slipped.
Risks That Could Keep the Target Out of Reach
The immediate obstacle is the fourth-quarter revenue outlook of $145 million to $150 million, which fell short of the roughly $151.6 million consensus and triggered the selloff. Government procurement cycles are also a known swing factor; if federal or international law enforcement budgets lag, bookings can slip. The broad analyst-target cuts in August and again at JPMorgan in November show that estimates are still being reset downward, and continued downward revisions or another guidance shortfall would keep pressure on the stock forecast.
Technical Levels and Market Structure
CLBT has been trading below its 50-day moving average, which sat near $11.61 in mid-November, and well under its 200-day average of roughly $13.45. The recent intraday low near $10.88 and the 52-week low of $9.58 mark key support levels. On the upside, the pre-earnings close near $12.70 and the $14 area represent resistance levels that the stock would need to reclaim before a push toward $14.50 becomes realistic. From what I see, watching these levels closely helps frame the risk-reward setup.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month horizon, though no firm horizon is guaranteed. The next earnings report, expected around February 2027, is the most important near-term catalyst, with focus on whether fourth-quarter revenue lands within guidance and whether 2027 guidance signals re-acceleration. Investors should also watch analyst revisions, government demand commentary, and the stock's ability to hold the $10 area and reclaim its 50-day moving average.
Final Assessment
The question of whether Cellebrite can reach $14.50 hinges on its ability to stabilize guidance and rebuild momentum after a sharp de-rating. The target, derived from a $14.40 mean of six recent analyst targets, implies about 26% upside and sits near the top of the current $12.50 to $15 range. Support comes from durable demand and a favorable long-term setup cited by JPMorgan, while the principal obstacles are the recent guidance shortfall, still-falling estimates, and technical resistance near $12.70. Whether the stock closes that gap will depend on execution over the next several quarters, and no outcome is guaranteed.
Using AI Daily Buy/Sell Signals in My Process
For traders looking to complement fundamental research with data-driven timing, I sometimes turn to Tickeron's AI Daily Buy/Sell Signals. These tools use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. In my experience, this adds a useful technical layer when evaluating names like CLBT alongside the analyst targets discussed above. Exploring these signals can help spot shifting trends more efficiently than manual review alone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Aroon Indicator for CLBT shows an upward move is likely
CLBT's Aroon Indicator triggered a bullish signal on November 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 214 similar instances where the Aroon Indicator showed a similar pattern. In 183 of the 214 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for CLBT crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +2.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLBT advanced for three days, in 221 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CLBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for CLBT moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 30 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 61 cases where CLBT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLBT as a result. In 68 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for CLBT turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 45 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
CLBT moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 63 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. CLBT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.815) is normal, around the industry mean (16.188). P/E Ratio (51.875) is within average values for comparable stocks, (45.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.427) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (103.301).
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ComputerCommunications
Advertisement